KRAS and lung cancer: For example, in non–small cell lung cancer (NSCLC) tissue and/or circulating tumor DNA, STK11 and KRAS alterations frequently occur together, and STK11 variants, especially when coupled with pathogenic KRAS variants, can lead to resistance against immunotherapy in these cancers [11].